Latest Bevacizumab Stories
TARRYTOWN, N.Y., Oct. 17, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
Analyses of PRiDe, a registry of 457 recurrent glioblastoma patients, show that patients treated with the NovoTTF(TM)-100A System at their first and second recurrences had median overall survivals
-- Phase III RAINBOW Trial Data Published in The Lancet Oncology -- INDIANAPOLIS, Sept.
-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept.
Introduction of Extended RAS Testing and Recent Clinical Trial Data Will Affect How Physicians Treat Colorectal Cancer Patients, According to Findings from Decision Resources Group BURLINGTON,
DelMar Is Advancing Clinical Trials With VAL-083 As A New Chemotherapy For Refractory Glioblastoma Multiforme VANCOUVER, British Columbia and MENLO PARK, Calif., Aug.
VAL-083 Phase I/II VAL-083 clinical trial advances to 50mg/m(2) cohort VANCOUVER, British Columbia and MENLO PARK, Calif., Aug.
Over Three-Quarters of Physicians View Ophthotech's Fovista as an Emerging Therapy with High Potential Value for Wet AMD, According to Findings from Decision Resources Group BURLINGTON, Mass.,
- A person in a secondary role, specifically the second most important character (after the protagonist).